Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of Oral RPC1063 (Ozanimod) in Moderate to Severe Ulcerative Colitis
2024-514815-92-00Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in autoimmune colitis, sponsored by Celgene Corporation. Primary endpoints: Clinical remission rate, Clinical response rate and 10 more. Started Aug 2024; status: completed.
02
Drugs
ozanimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-514815-92-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514815-92-00.